Skip to content
Screener

Septerna, Inc. SEPN Total Equity

Total Equity at other companies

Amgen logo
AmgenAMGN
$11.69B+57.4%
Tectonic Therapeutics logo
Tectonic TherapeuticsTECX
$230.42M-23.5%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$394.88M+12.8%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$422.93M+60.5%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$402.63M-10.0%
Schrodinger logo
SchrodingerSDGR
$328.96M-4.1%

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Cash & equivalents$71.6M-65.9%
Total debt$23.1M-7.7%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.78B+240%
Enterprise value$1.73B+383%
P/S24.7×-696×

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Return on equity-12.2%
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Reported directly by Septerna, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Septerna, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:08 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216759
Line itemMarch 31, 2026December 31, 2025
Stockholders' equity:
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025
Common stock, $0.001 par value per share, 500,000,000 shares authorized at March 31, 2026 and December 31, 2025; 44,916,572 and 44,806,272 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively; 75,247 and 131,224 shares subject to repurchase as of March 31, 2026 and December 31, 2025, respectively4545
Additional paid-in capital554,872548,517
Accumulated other comprehensive (loss) income(569)617
Accumulated deficit(175,890)(167,253)
Total stockholders' equity378,458381,926
Total liabilities and stockholders' equity$569,688$596,187

Item 1. Condensed Financial Statements.

FAQ

What is Septerna, Inc.'s total equity?
Septerna, Inc. (SEPN) reported total equity of $378.46M in Q1 2026.
How has Septerna, Inc.'s total equity changed year-over-year?
Septerna, Inc.'s total equity increased by 194.6% year-over-year, from -$400.27M to $378.46M.
What is the long-term trend for Septerna, Inc.'s total equity?
Over 3 years (2022 to 2025), Septerna, Inc.'s total equity has grown at a 105.2% compound annual growth rate (CAGR), from -$44.2M to $381.93M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Septerna, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude